Search Page 1/1: statin intolerance. 15 result found: ICD-10-CM Diagnosis Code E73.9 [convert to ICD-9-CM] Lactose intolerance, unspecified. Intestinal disaccharidase deficiency; Lactose intolerance. ICD-10-CM Diagnosis Code E73.9. Lactose intolerance, unspecified. 2016 2017 2018 2019 2020 2021 2022 Billable/Specific Code.
Dec 26, 2020 · (Rational- Physician has provided treatment for myopathy due to statin due to which we should code G72.0 and T46.6X5A and we should not code status of statin intolerance i.e Z88.8)) Spread the love Tags allergy to statin icd 10 , icd 10 code for intolerance to statin , icd 10 for intolerance to statin , statin allergy icd 10 , statin ...
Dec 14, 2017 · Medical Coding Cardiology ICD-10-CM for Statin Intolerance Cardio403 Dec 14, 2017 C Cardio403 New Messages 8 Best answers 0 Dec 14, 2017 #1 We have been having a debate about which 7th digit should use with code: T46.6X5- when a patient has know intolerance to statin medication.
Mar 02, 2020 · acceptable exclusionary diagnoses for the Statin Therapy for Patients with Cardiovascular Disease measure. ICD10 Exclusion Codes in place for HEDIS 2020 reporting: G72.0 Drug-induced myopathy G72.2 Myopathy due to other toxic agents G72.9 Myopathy, unspecified M60.9 Myositis, unspecified M62.82 Rhabdomyolysis M79.1 Myalgia M79.10 …
As the name suggests, statin intolerance occurs when a patient is unable to continue to use a statin, either because of the development of a side effect or because of evidence on a blood test that certain markers of liver function or muscle function (creatine kinase) are sufficiently abnormal to cause concern.Mar 31, 2015
ICD-10-CM Code for Unspecified adverse effect of drug or medicament T88. 7.
Valid for SubmissionICD-10:T46.6X5AShort Description:Adverse effect of antihyperlip and antiarterio drugs, initLong Description:Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter
Statin intolerance occurs when a person develops side effects from statin use. There are different symptoms you may experience. The most common is muscle pains or cramps, also called myalgias. You may experience muscle inflammation and an elevated marker of muscle injury called creatine kinase.
ICD-10-PCS GZ3ZZZZ is a specific/billable code that can be used to indicate a procedure.
ICD-10 code Z79. 899 for Other long term (current) drug therapy is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
Statins include atorvastatin (Lipitor), fluvastatin (Lescol XL), lovastatin (Altoprev), pitavastatin (Livalo), pravastatin (Pravachol), rosuvastatin (Crestor, Ezallor) and simvastatin (Zocor, FloLipid). Having too much cholesterol in your blood increases your risk of heart attacks and strokes.
ICD-10 Codes for Long-term TherapiesCodeLong-term (current) use ofZ79.84oral hypoglycemic drugsZ79.891opiate analgesicZ79.899other drug therapy21 more rows•Aug 15, 2017
Atorvastatin is in a class of medications called HMG-CoA reductase inhibitors (statins). It works by slowing the production of cholesterol in the body to decrease the amount of cholesterol that may build up on the walls of the arteries and block blood flow to the heart, brain, and other parts of the body.Jul 20, 2021
There are many non-statin medications your doctor might prescribe: Bile acid-binding resins, like cholestyramine (Locholest, Prevalite, Questran), colesevelam (WelChol), and colestipol (Colestid) stick to cholesterol-rich bile acids in your intestines and lower your LDL levels.Jan 5, 2018
Diagnosing Statin IntoleranceBlood tests to rule out other conditions.Genetic tests to see if you are more prone to statin intolerance.Muscle biopsy to check for creatine production.Symptoms questionnaire to provide more in-depth information about your symptoms, medications, and family medical history More items...•Jun 1, 2021
Studies show that about 5 percent to 10 percent of people are unable to tolerate statins, largely because of muscle aches and related side effects, including potential muscle damage.Jun 1, 2018
The previously validated ACD algorithm identified 2 types of statin intolerance over 2 years after initiating a statin ( Figure 1 ): (1) absolute statin intolerance, including with and without rhabdomyolysis, and (2) dose titration statin intolerance. To be classified as having absolute statin intolerance with rhabdomy-olysis, patients were required to (a) stop filling a prescription for a single statin; (b) have a medical claim for rhabdomy-olysis; (c) have no additional prescription fills for a statin after the adverse event (i.e., rhabdomyolysis); and (d) have at least 100 days left in the study period. 20 Absolute statin intolerance without rhabdomyolysis was similarly defined, except patients were required to stop filling at least 2 different statins, and adverse events other than rhabdomyolysis (e.g., creatinine kinase tests, myalgia/myositis, arthralgia, myopathy, other muscle toxicity, nausea, constipation, diarrhea, other gastrointestinal distress, anaphylaxis, rash/facial flushing, and cognitive impairment) were included.
The MP and ACD algorithms had mixed concordance, with high scores related to negative statin intolerance classification but relatively poor scores for those associated with positive identification of statin intolerance. Both algorithms used a combination of pharmacy and medical claims and may be useful for all health care delivery organizations (e.g., integrated delivery networks and accountable care organizations) in identifying patients with statin intolerance. In addition, given the proportion of patients classified as statin intolerant via prescription fill patterns, both algorithms may be useful for pharmacy benefit managers as well. By identifying patients with statin intolerance, health care delivery systems may use population health management strategies to help reduce the risk of cardiovascular events in these patients.
This study has several limitations worthy of discussion. First, the MP algorithm was not independently validated against medical records. However, the ACD algorithm was based on administrative claims data and validated against medical records (sensitivity 0.78, specificity 0.98, PPV 0.64, NPV 0.99, and Cohen’s κ 0.66) so serves as an acceptable reference group for the concordance of the MP algorithm. 20 In addition, the application of the ACD algorithm to the population in this study identified fewer patients with statin intolerance than in the validation study (current study 5.4% vs. validation study 14.0%). In the validation study, the majority of patients with statin intolerance were classified as having titration intolerance (11.8%). This study was performed in a commercially insured population in the Intermountain Region, and the differences seen in statin intolerance incidence may be a result of differences in patient and provider practices between the populations. In this study, only 5.4% of patients decreased to a lower statin dose. Future studies are warranted to examine the statin prescription fill patterns in larger, more nationally representative populations.
The joint use of the algorithms may be useful for all health care delivery organizations (e.g., integrated delivery network, pharmacy benefit managers, and accountable care organizations) in identifying patients with statin intolerance to help reduce cardiovascular event risk in these patients.